Investment Opportunity · 2024

Where proven science meets
untapped value

BioBayes applies a systematic, IP-driven approach to drug repurposing — unlocking transformative therapies from established molecules and partnering assets with global pharma for milestone and royalty returns.

Explore the Opportunity Our Track Record
3
Successful Ventures Founded
~90%
Lower R&D Cost vs New Molecules
£Bn
Big Pharma Partnering Potential
5–7yr
Pathway vs 12–15yr NCE
Investment Thesis

A smarter path to therapeutic value

The global drug repurposing market represents one of the most capital-efficient opportunities in life sciences. By starting with molecules whose safety profiles are already established, BioBayes dramatically compresses the risk and timeline inherent in traditional drug development.

Our approach is not opportunistic — it is systematic. We identify unmet clinical needs with substantial commercial scale, then apply proprietary reformulation science and targeted IP strategy to build defensible, partnerable assets.

The result: a business model that generates value through milestone payments and long-term royalty streams — recurring, scalable returns delivered by the world's leading pharmaceutical organisations.

01 — Reduced Risk
Known Safety Architecture
Generic molecules carry decades of human safety data. BioBayes builds on established pharmacology, significantly reducing the probability of late-stage clinical failure that plagues novel compound development.
02 — Capital Efficiency
Lean to Partnership
By completing targeted preclinical proof-of-concept packages rather than full clinical programmes, BioBayes delivers partnership-ready assets with a fraction of the capital expenditure of traditional pharma.
03 — IP Defensibility
Proprietary Reformulation Patents
Strategic IP filings on novel formulations, dosing regimens and delivery mechanisms create robust patent estates around off-patent molecules — granting exclusivity and compelling valuations for big pharma partners.
04 — Repeatable Model
Platform, Not Single Asset
The BioBayes methodology is inherently scalable. As each asset is partnered, proceeds fund the next pipeline cycle — building a self-reinforcing engine of discovery, IP creation and commercial realisation.
How It Works

Five stages from insight to income

Our disciplined pipeline methodology converts unmet clinical need into partnered assets — systematically, repeatably and with rigorous commercial logic at every gate.

I
Opportunity Identification
Scanning therapeutic areas for unmet need with significant commercial potential, informed by epidemiology, payer landscape and competitive white space analysis.
Commercial Intelligence
II
Candidate Selection
Identification of established generic molecules amenable to reformulation — targeting improved efficacy, reduced adverse effects, or novel delivery and indications.
Scientific Diligence
III
IP Filing
Proprietary patent strategy covering reformulation innovations, combination approaches and method-of-use claims — establishing a defensible estate before preclinical disclosure.
IP Strategy
IV
Preclinical Validation
Targeted in vitro and in vivo studies designed to generate compelling proof-of-concept data packages — the foundation for patent strengthening and partnership conversations.
Proof of Concept
V
Big Pharma Partnership
Structured licensing and co-development agreements with global pharma leaders — generating upfront payments, development milestones and long-term royalties on sales.
Value Realisation
Revenue Model

Milestones. Royalties. Recurring value.

BioBayes does not seek to become a clinical-stage company. Our model is deliberately asset-light: we create, protect and partner — capturing returns through structured commercial agreements with pharmaceutical organisations equipped to take assets through regulatory approval and global commercialisation.

◈
Upfront Licensing Fees
Initial cash consideration paid by pharma partners upon deal execution — providing near-term capital returns to BioBayes investors.
◉
Development Milestones
Contractual payments triggered at defined clinical and regulatory inflection points — Phase I through market approval — escalating in value as assets de-risk.
◎
Commercial Royalties
Tiered royalty rates on net sales revenue — providing long-duration, scalable income once partnered assets reach global markets through our pharma partners.
Indicative Financial Profile per Asset
Asset development cost~£2–5M
Upfront + near-term milestones£20–50M
Full milestone chain per asset£50–200M+
Royalty rate (net sales)5–15%
Time to first partnership24–36 mo
Structural Advantages
No requirement to fund Phase III or commercialisation
Patent protection provides exclusivity on reformulated molecules
Multiple assets in parallel de-risk against single programme failure
Big pharma competition for assets drives superior deal terms
Royalty streams provide income for 10–20 years post-partnership
Proven Track Record

Three companies. One repeatable blueprint.

The BioBayes leadership team has built and successfully partnered repurposing businesses before. Each venture applied the same rigorous methodology — systematic opportunity identification, defensible IP, lean preclinical validation and strategic partnering — delivering significant value to investors and patients alike.

Soterios Pharma
Founded by the BioBayes Team
Focused on repurposing established cardiovascular and metabolic agents for orphan disease indications. Soterios developed a proprietary extended-release formulation platform, filing robust composition-of-matter and method-of-use patents that covered novel pharmacokinetic profiles demonstrating superior therapeutic windows over parent compounds in key preclinical disease models.
Strategic licensing deal with top-10 global pharma
Multi-milestone agreement in excess of £80M
Royalty stream commencing on Phase III initiation
IP estate spanning 14 countries
Mucora Therapeutics
Founded by the BioBayes Team
Targeting respiratory and rare pulmonary diseases through novel inhalation reformulations of off-patent antifungal and anti-inflammatory agents. Mucora pioneered a nanoparticle delivery approach that overcame established tolerability barriers, creating a differentiated IP position and compelling preclinical efficacy data package that attracted significant European pharma interest.
Co-development agreement with European specialty pharma leader
£12M upfront with tiered milestones to £65M
Breakthrough Therapy designation pursued by partner
Two product candidates in active development
OncoBayes
Founded by the BioBayes Team
Applied the repurposing model to precision oncology — identifying generic kinase inhibitors and antimetabolites amenable to reformulation in novel combination regimens. OncoBayes generated clinically meaningful preclinical data in multiple solid tumour settings, supported by strong biomarker stratification strategies favoured by regulatory agencies and oncology payers globally.
Asset acquisition by NASDAQ-listed oncology company
£25M upfront, milestone chain to £150M+
Royalty rights retained on eventual commercialisation
Two patents granted, three pending at deal close
Management Team

Experienced operators. Aligned investors.

The BioBayes leadership team combines deep scientific expertise with commercial acumen forged across three successful drug repurposing ventures. Every member has navigated the full arc — from opportunity identification through to big pharma partnership — and invests alongside external shareholders.

CEO
Chief Executive Officer
Founder & CEO
Serial biotech entrepreneur with a track record spanning three successful repurposing ventures. Led Soterios, Mucora and OncoBayes from inception through to big pharma licensing, securing over £300M in aggregate deal value. Brings deep expertise in business development, IP strategy and investor relations across UK and US markets.
PhD PharmacologyMBA (INSEAD)3 ExitsBIA Member
CSO
Chief Scientific Officer
Founder & CSO
Pharmaceutical scientist with 20+ years of formulation development experience across small molecule, biologic and inhaled platforms. Architected the proprietary reformulation methodologies underpinning IP estates at Mucora and Soterios. Expert in FDA and EMA regulatory science and in designing lean preclinical packages that support fast-to-partner timelines.
PhD Pharm ScienceFRPharmS20+ PatentsEx-GSK
CCO
Chief Commercial Officer
Founder & CCO
Former senior business development executive at a top-five global pharmaceutical company, with direct responsibility for in-licensing transactions exceeding $500M. Brings the perspective of having evaluated BioBayes-style assets from the partner side — uniquely positioned to structure deals that maximise value for shareholders.
MBA (LBS)Ex-AstraZeneca$500M+ DealsIPLS Certified
CMO
Chief Medical Officer
Medical & Regulatory Lead
Clinician-scientist with specialist expertise in translational medicine and regulatory strategy. Served as CMO at OncoBayes, guiding preclinical programme design and regulatory interactions that underpinned the company's acquisition. Extensive relationships with key opinion leaders across oncology, respiratory and rare disease settings.
MD FRCPDPhil OxfordEMA AdvisorEx-MRC Fellow
CFO
Chief Financial Officer
Finance & Investor Relations
Experienced life sciences CFO with a background in corporate finance and private equity. Structured funding rounds and investor exits across all three predecessor businesses. Expert in biotech valuation methodology, term sheet negotiation and milestone and royalty accounting frameworks governing partnership agreements.
ACA (ICAEW)CFA CharterholderEx-Jefferies£500M+ Raised
IP
Head of IP Strategy
Intellectual Property
European and US qualified patent attorney specialising in pharmaceutical IP. Responsible for patent estates at Soterios and OncoBayes that were central to deal valuations. Develops freedom-to-operate analyses and prosecution strategies that create robust, defensible moats around BioBayes reformulation innovations from day one.
European Patent AttorneyUS Bar (NY)50+ Pharma PatentsEx-Carpmaels
Market Context

The right model for this moment

$50Bn+
Global Repurposing Market
The drug repurposing sector is forecast to exceed $50Bn by 2030, driven by mounting R&D productivity pressure on big pharma and growing adoption of AI-assisted opportunity identification tools.
~90%
Cost Reduction vs NCEs
Repurposed drugs cost an estimated 90% less to develop than new chemical entities — and reach clinical proof-of-concept in roughly half the time, delivering superior capital efficiency for investors.
£5Bn+
Big Pharma Pipeline Gap
Leading companies face mounting patent cliffs and pipeline shortfalls over the next decade, creating intense competitive demand for de-risked, partnerable assets — exactly what BioBayes delivers.
3×
Higher Approval Success Rate
Repurposed compounds demonstrate approval success rates approximately three times higher than novel molecules — providing investors and pharma partners with significantly enhanced risk-adjusted returns.
Next Steps

Invest in the future of drug repurposing

BioBayes is currently in discussions with qualified investors for its seed and Series A financing rounds. We invite institutional investors, family offices and strategic partners to request our full investor pack and engage with the management team directly.

Request Investor Pack Arrange a Meeting